Showing results (2361-2370 of 2,690) with videos related to
Sort By:
Pageof 269
Journal for Immunotherapy of Cancer|October 24, 2019
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapiesZijun Y Xu-Monette, Jianyong Li, Yi Xia, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2022
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell LymphomaZijun Y Xu-Monette, Li Wei, Xiaosheng Fang, et al.Oncotarget|November 18, 2015
Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphomaQing Ye, Zijun Y Xu-Monette, Alexandar Tzankov, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphomaChi Young Ok, Jiayu Chen, Zijun Y Xu-Monette, et al.Neuro-Oncology Advances|May 31, 2021
Timing of glioblastoma surgery and patient outcomes: a multicenter cohort studyDomenique M J Müller, Merijn E De Swart, Hilko Ardon, et al.Cancer Research|December 1, 2023
Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic PlasticityDominik Awad, Pham Hong Anh Cao, Thomas L Pulliam, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 22, 2023
Detection of Second Primary Lymphoma in Late Diffuse Large B-cell Lymphoma RecurrencesMadeleine R Berendsen, Diede A G van Bladel, Eva Hesius, et al.Journal of Hematology & Oncology|November 5, 2020
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53Manman Deng, Mingzhi Zhang, Zijun Y Xu-Monette, et al.Oncoimmunology|August 5, 2021
Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphomaHua You, Zijun Y Xu-Monette, Li Wei, et al.Aging|December 13, 2016
RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphomaMingzhi Zhang, Zijun Y Xu-Monette, Ling Li, et al.Pageof 269